Matches in Wikidata for { <http://www.wikidata.org/entity/Q80365420> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- Q80365420 description "assaig clínic" @default.
- Q80365420 description "clinical trial" @default.
- Q80365420 description "clinical trial" @default.
- Q80365420 description "clinical trial" @default.
- Q80365420 description "clinical trial" @default.
- Q80365420 description "ensaio clínico" @default.
- Q80365420 description "ensayo clínico" @default.
- Q80365420 description "ensayu clínicu" @default.
- Q80365420 description "essai clinique" @default.
- Q80365420 description "klinisch onderzoek" @default.
- Q80365420 description "клінічне випробування" @default.
- Q80365420 name "A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer." @default.
- Q80365420 name "A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer." @default.
- Q80365420 type Item @default.
- Q80365420 label "A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer." @default.
- Q80365420 label "A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer." @default.
- Q80365420 prefLabel "A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer." @default.
- Q80365420 prefLabel "A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer." @default.
- Q80365420 P1132 Q80365420-5E7C51FE-33F7-4BFF-80F0-0D48078A6C52 @default.
- Q80365420 P1476 Q80365420-824EFF86-347A-4AEB-AB94-ACC68CC41BB0 @default.
- Q80365420 P17 Q80365420-0350C852-E4BF-4BFB-8846-9FD85432A9B4 @default.
- Q80365420 P17 Q80365420-1A5173AE-E221-4070-9212-4BF0F8EEF95A @default.
- Q80365420 P17 Q80365420-2398AAE3-452F-4138-9B98-C8C420B8AA14 @default.
- Q80365420 P17 Q80365420-277BC46D-8343-435E-8436-089259BD7680 @default.
- Q80365420 P17 Q80365420-308C7BCE-3289-4921-A850-E9D2EB258309 @default.
- Q80365420 P17 Q80365420-4A537028-31F6-4B5D-9CB3-687EEAFEBCC0 @default.
- Q80365420 P17 Q80365420-4E49CAC1-D31A-46ED-8AED-59C8240E5BC8 @default.
- Q80365420 P17 Q80365420-5F924216-47A7-42FE-B655-741D3AA00DEE @default.
- Q80365420 P17 Q80365420-61BE0F95-B778-445A-8B59-23EA7CC5E0AE @default.
- Q80365420 P17 Q80365420-7A4DDAE8-B45D-49CA-AEA1-B46255126FFA @default.
- Q80365420 P17 Q80365420-AEA8374C-9E6B-4436-A36B-DE72FF12D4DD @default.
- Q80365420 P17 Q80365420-D61B3495-4597-4351-8021-8FF6C9263C53 @default.
- Q80365420 P17 Q80365420-E10BBA5E-D46B-4672-87B7-F6C31C526359 @default.
- Q80365420 P17 Q80365420-EDD6B7FE-1E2B-4E2C-805F-BA5BEC1D7722 @default.
- Q80365420 P17 Q80365420-FDDBA45B-03CB-42F5-AE59-9F2B2915AE6B @default.
- Q80365420 P2899 Q80365420-4886095E-C50B-4E11-90A6-C9323920E05F @default.
- Q80365420 P3098 Q80365420-985176B7-A50E-4754-8A7B-85F45DD3D4C0 @default.
- Q80365420 P31 Q80365420-75C5071B-167A-491B-BD85-76729C574867 @default.
- Q80365420 P4844 Q80365420-60C4443C-1FAA-40A7-8C9C-844E26E69DAC @default.
- Q80365420 P580 Q80365420-BA872224-4402-42EE-A9B8-70CB85A7D989 @default.
- Q80365420 P582 Q80365420-208E9549-FB78-41C7-A0D7-23C71A026FED @default.
- Q80365420 P6099 Q80365420-A7D248A6-36EC-4F9D-A2F9-1306A1330B8C @default.
- Q80365420 P767 Q80365420-2710AFC0-EE4C-476E-AFBF-BC723AA38899 @default.
- Q80365420 P8363 Q80365420-4CBA01AB-2490-4157-A1EF-21C010F503EC @default.
- Q80365420 P859 Q80365420-2E702D8A-B2A6-41B9-8EEF-1D1EF8B804EF @default.
- Q80365420 P921 Q80365420-0D579B26-FDB4-4AA8-A7D6-913F397058CF @default.
- Q80365420 P1132 "+540" @default.
- Q80365420 P1476 "A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible" @default.
- Q80365420 P17 Q142 @default.
- Q80365420 P17 Q145 @default.
- Q80365420 P17 Q155 @default.
- Q80365420 P17 Q16 @default.
- Q80365420 P17 Q183 @default.
- Q80365420 P17 Q29 @default.
- Q80365420 P17 Q30 @default.
- Q80365420 P17 Q31 @default.
- Q80365420 P17 Q36 @default.
- Q80365420 P17 Q40 @default.
- Q80365420 P17 Q408 @default.
- Q80365420 P17 Q41 @default.
- Q80365420 P17 Q414 @default.
- Q80365420 P17 Q55 @default.
- Q80365420 P17 Q664 @default.
- Q80365420 P2899 "+18" @default.
- Q80365420 P3098 "NCT04209114" @default.
- Q80365420 P31 Q30612 @default.
- Q80365420 P4844 Q412415 @default.
- Q80365420 P580 "2020-01-15T00:00:00Z" @default.
- Q80365420 P582 "2024-07-15T00:00:00Z" @default.
- Q80365420 P6099 Q42824827 @default.
- Q80365420 P767 Q17114308 @default.
- Q80365420 P8363 Q78089383 @default.
- Q80365420 P859 Q266423 @default.
- Q80365420 P921 Q7041828 @default.